Insulin detemir results in less weight gain than NPH insulin when added to oral agents in type 2 diabetes, with this advantage increasing with baseline obesity

被引：0
|
作者：
Hermansen, K
Tamer, SC
机构：
[1] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[2] Novo Nordisk, Copenhagen, Denmark
来源：
DIABETOLOGIA | 2005年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5
引用
收藏
页码：A4 / A5
页数：2
相关论文
共 50 条
  • [21] How do detemir and glargine compare when added to oral agents in insulin-naive patients with type 2 diabetes mellitus?
    Marks, Jennifer B.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (09): : 490 - 491
  • [22] Indian Patients with Diabetes Experienced Better Glycemic Control, Less Weight Gain and Hypoglycaemia with Insulin. Detemir When Switched from NPH and Insulin Glargine in PREDICTIVE™ Study
    Kesavadev, Jothydev
    Singh, Parminder
    Pitle, Shailesh Umakant
    Bhttacharyya, Arpandev
    Mayya, Raghavendra
    Moharana, Ashok Kumar
    Pathak, Ankit
    Kalra, Sanjay
    DIABETES, 2009, 58 : A528 - A528
  • [23] Insulin glargine is associated with less hypoglycaemia than NPH insulin in older patients with Type 2 diabetes
    Riddle, M
    Massi-Benedetti, M
    Häring, HU
    Dailey, G
    Murray, F
    Lin, Z
    Rosenstock, J
    DIABETOLOGIA, 2004, 47 : A328 - A328
  • [24] Use of insulin deternir once-daily results in less weight gain compared with the use of NPH insulin, particularly in obese subjects with type 2 diabetes
    Philis-Tsimikas, A.
    Koenen, C.
    Pedersen, C. B.
    Thorsteinsson, B.
    DIABETOLOGIA, 2007, 50 : S404 - S404
  • [25] Insulin Detemir Increases Cerebral Glucose Metabolism Compared to NPH Insulin in Human Type 1 Diabetes: Possible Explanation for Differences in Weight Gain?
    Van Golen, Larissa W.
    Huisman, Marc C.
    Ijzerman, Richard G.
    Hoetjes, Nikie J.
    Schwarte, Lothar A.
    Schober, Patrick
    Hoogma, Roel P.
    Drent, Madeleine L.
    Lammertsma, Adriaan A.
    Diamant, Michaela
    DIABETES, 2011, 60 : A421 - A421
  • [26] How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?
    Jennifer B Marks
    Nature Clinical Practice Endocrinology & Metabolism, 2008, 4 : 490 - 491
  • [27] How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?
    Christoph Koenen
    Nature Clinical Practice Endocrinology & Metabolism, 2008, 4 (10): : E1 - E1
  • [28] Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes
    Haak, T
    Tiengo, A
    Draeger, E
    Suntum, M
    Waldhäusl, W
    DIABETES OBESITY & METABOLISM, 2005, 7 (01): : 56 - 64
  • [29] Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes
    Vos, Rimke C.
    Rutten, Guy E. H. M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (15): : 1489 - 1490
  • [30] Improved efficacy when insulin detemir is added to OADs in Indian subjects with type 2 diabetes
    Ambady, Ramachandran
    Kumar, Fiarish
    Annamalai, Sundaram
    Patel, Mayur
    Gupta, Sunil
    Venkatanarasimhachar, Srishyla M.
    DIABETES, 2006, 55 : A469 - A470
12345